Vellekoop L, Jagannath S, Spitzer G, Zander A R, Horwitz L J, Keating M, McCredie K B, Dicke K A
Am J Clin Oncol. 1986 Aug;9(4):307-10. doi: 10.1097/00000421-198608000-00006.
High-dose cyclophosphamide, 1,3-bis-(2 chloroethyl)-1-nitrosourea (BCNU), and VP-16-213 followed by autologous bone marrow rescue was administered to 29 adult patients with acute leukemia in relapse who had failed to respond to prior salvage treatment, with the following results: 14 patients (48%) achieved complete remission (CR), two patients died early of infection and hemorrhage during hypoplasia, and 13 patients had relapsed with leukemia after an initial hypo-plastic phase. Median remission duration was 3 1/2 months (range, 1-8 months). Maintenance treatment with cyclophosphamide and VP-16, which was given to six patients, did not prolong remission duration. Subsequent salvage treatment was well tolerated by both responders and patients who failed to reach CR. This regimen, which is active in both acute lymphocytic leukemia and acute myelogenous leukemia, had a mild toxicity.
对29例复发的成年急性白血病患者给予大剂量环磷酰胺、1,3 - 双（2 - 氯乙基）- 1 - 亚硝基脲（卡莫司汀，BCNU）和依托泊苷（VP - 16 - 213），随后进行自体骨髓挽救治疗，这些患者对先前的挽救治疗无效，结果如下：14例患者（48%）实现完全缓解（CR），2例患者在骨髓抑制期因感染和出血早期死亡，13例患者在初始骨髓抑制期后白血病复发。中位缓解持续时间为3.5个月（范围1 - 8个月）。6例患者接受环磷酰胺和VP - 16维持治疗，但并未延长缓解持续时间。缓解者和未达到CR的患者对后续挽救治疗耐受性良好。该方案对急性淋巴细胞白血病和急性髓性白血病均有效，且毒性轻微。
